Sun Pharmaceutical Industries was up 2.14% to Rs 515.50 at 9:33 IST on BSE after the company secured approval from US drug regulator for a psoriasis treatment drug.
The announcement was made after market hours yesterday, 21 March 2018.Meanwhile, the S&P BSE Sensex was up 86.02 points or 0.26% at 33,231.15.
On the BSE, 1.21 lakh shares were traded on the counter so far as against the average daily volumes of 7.62 lakh shares in the past one quarter. The stock had hit a high of Rs 521.90 and a low of Rs 512.40 so far during the day. The stock had hit a 52-week high of Rs 709.80 on 24 March 2017 and a 52-week low of Rs 433.15 on 14 August 2017.
The large-cap company has equity capital of Rs 239.93 crore. Face value per share is Rs 1.
Sun Pharmaceutical Industries announced that the United States Food and Drug Administration (FDA) has approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
On a consolidated basis, net profit of Sun Pharmaceuticals Industries declined 76.8% to Rs 400.17 crore on 14.1% decline in net sales to Rs 6598.21 crore in Q3 December 2017 over Q3 December 2016.
Sun Pharma is one of the leading specialty generic pharmaceutical companies in the world and India's top pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
